ePoster
Die hochgeladenen ePoster sind nur für eingeloggte Teilnehmende ersichtlich.
Bitte loggen Sie sich ein, um zu den ePoster zu gelangen.
Detaillierte Beitrags-Information
| Beitragstitel | Outcomes of the minimal invasive glaucoma implant (iStent Inject) as a stand-alone procedure and Phaco combined with iStent Inject in a Swiss population |
|---|---|
| Beitragscode | P08 |
| Autor:innen | |
| Präsentationsform | ePoster |
| Themengebiete |
|
| Abstract-Text |
Purpose The iStent Inject has previously demonstrated efficacy in the reduction of intraocular pressure (IOP) and glaucoma medication (AGD) as a stand-alone procedure and combined with phaco. Yet, it is anecdotally reported as less potent than studies state. The clinical data of a tertiary centre in Switzerland was revisited to review the outcomes of istent Inject implantations in the domains of IOP, AGD and refraction. Methods Electronic health records of patients who underwent either iStent Inject implantation alone, or combined phacoemulsification, lens and iStent Inject implantation performed by one surgeon (MTH) were evaluated retrospectively. The records were assessed for IOP, AGD, refraction preoperatively and at follow-up with descriptive statistical evaluation. Results Twenty-six patients underwent iStent Inject implantation, 11 as a stand-alone procedure (iStent alone) and 13 as a combined procedure (iStent +). Median age was 80, min/max (57/90) years in the iStent alone and 77, (60/85) years in the iStent + group. At baseline, the IOP for iStent alone measured 20, min/max (13/37) mmHg, at one month post-OP 18, (6/32) mmHg, minus 10% compared to baseline, at three months 18, (12/27) mmHg, minus 10% compared to baseline. In the iStent inject + group IOP at baseline was 18, min/max (11/24) mmHg; at one month post-OP 13, (11/18) mmHg, minus 28 % compared to baseline and at three months 13, (11/16) mmHg, minus 28% compared to baseline. At baseline a mean of two AGD agents were applied in both groups. At one and three month(s) post-OP, it was unchanged for the iStent alone group and reduced to one AGD in the iStent + group. At baseline, the median spherical equivalent (SE) in the iStent alone group was -0.75, min/max (-6.875/+2.5)D and +0.125, (-3.25/+1.875)D in the iStent+ group. After three months the median SE in the iStent alone group was -1.0, (-6.88/-0.23)D and 0.0, (-0.875/+0.25)D after a median target refraction of -0.31, (-0.51/0.0) D in the iStent+ group. Conclusion iStent inject implantation as a stand-alone procedure had a mild IOP lowering effect in a Swiss population over three months time. It had no effect on refraction or number of applied AGDs. Compared to literature, in the presented patient group, IOP reduction and effect on AGD was lower than previously reported. The results of the combined procedure with regards to IOP and AGD were comparable to, yet at the lower end of previously reported findings. |